Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lymphoproliferative Disorder Following Transplantation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06815003
What this trial is testing

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+3 more
City of Hope Medical Center 35
Testing effectiveness (Phase 2)Study completedNCT00006251
What this trial is testing

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Who this might be right for
Acute Undifferentiated LeukemiaAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma+61 more
Fred Hutchinson Cancer Center 21
Early research (Phase 1)Study completedNCT01342289
What this trial is testing

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

Who this might be right for
Hodgkin's LymphomaLeukemiaMyelodysplastic Syndrome(MDS)+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 127
Large-scale testing (Phase 3)Looking for participantsNCT05243797
What this trial is testing

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 1,594
Large-scale testing (Phase 3)UnknownNCT02354313
What this trial is testing

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients

Who this might be right for
MANTLE CELL LYMPHOMA
Fondazione Italiana Linfomi - ETS 300
Testing effectiveness (Phase 2)Ended earlyNCT01045382
What this trial is testing

MSC and HSC Coinfusion in Mismatched Minitransplants

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphoblastic, AcuteLeukemia, Myelocytic, Chronic+6 more
University of Liege 39
Large-scale testing (Phase 3)Looking for participantsNCT06724237
What this trial is testing

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type+1 more
Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)Ended earlyNCT01135329
What this trial is testing

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Who this might be right for
LymphomaLeukemiaMyelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 15
Testing effectiveness (Phase 2)Looking for participantsNCT06505369
What this trial is testing

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
North Estonia Medical Centre 50
Early research (Phase 1)Study completedNCT01700751
What this trial is testing

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Who this might be right for
Leukemia, Acute MyeloidLeukemia, Lymphoblastic,AcuteMyelodysplastic Syndromes
Washington University School of Medicine 17
Testing effectiveness (Phase 2)Study completedNCT01790737
What this trial is testing

First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02

Who this might be right for
Multiple Myeloma
Kuopio University Hospital 80
Testing effectiveness (Phase 2)Ended earlyNCT00450983
What this trial is testing

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Fred Hutchinson Cancer Center 1
Testing effectiveness (Phase 2)Ended earlyNCT00961142
What this trial is testing

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
University Hospital Tuebingen 23
Testing effectiveness (Phase 2)Looking for participantsNCT06793410
What this trial is testing

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Who this might be right for
Recipients of Allogeneic Stem Cell TransplantationHPV (Human Papillomavirus)-AssociatedAcute Myeloid Leukaemia+2 more
Vastra Gotaland Region 100
Testing effectiveness (Phase 2)UnknownNCT06141304
What this trial is testing

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Who this might be right for
Relapsed Adult ALLRelapsed Adult AML
The First Hospital of Jilin University 28
Testing effectiveness (Phase 2)Study completedNCT01795378
What this trial is testing

Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphoblastic Leukemia
Asan Medical Center 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT03057795
What this trial is testing

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center 62
Testing effectiveness (Phase 2)Ended earlyNCT01875237
What this trial is testing

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Who this might be right for
LeukemiaMyelomaMyeloproliferative Diseases
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT00003402
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
University of Maryland, Baltimore 35
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Next Page
294